VarmX has enrolled the first participant in EquilibriX-S, a global randomized Phase 3 trial testing whether its engineered coagulation protein VMX-C001 can rapidly restore hemostasis in patients taking direct Factor Xa inhibitors who unexpectedly require urgent surgery or another high-bleeding-risk procedure. ClinicalTrials.gov lists an estimated enrollment of 800 participants, while VarmX says recruitment will span more than 20 countries and support worldwide regulatory submissions if the programme succeeds.
The candidate is unusual because it does not primarily try to remove the anticoagulant or bind it directly. VMX-C001 is a recombinant modified human Factor X protein engineered to function despite the presence of Factor Xa inhibitors, effectively providing a route around anticoagulation so that the coagulation cascade can operate again. VarmX is evaluating a fixed intravenous dose regardless of which Factor Xa inhibitor the patient received, with the pivotal study comparing VMX-C001 against usual pharmacological care immediately before urgent procedures.
Why are Factor Xa inhibitors difficult when emergency surgery cannot wait?
Direct oral Factor Xa inhibitors such as apixaban and rivaroxaban have replaced warfarin for many patients because they provide predictable anticoagulation without routine INR monitoring and substantially simplify long-term treatment. Those advantages become problematic when a patient suffers major trauma, needs emergency neurosurgery or develops another condition requiring an invasive procedure before the anticoagulant has cleared sufficiently.
Waiting may reduce bleeding risk but can be clinically impossible. Proceeding without adequate reversal can expose the patient to substantial operative hemorrhage.
Hospitals currently use strategies including prothrombin complex concentrates and specific reversal agents depending on clinical circumstances, drug exposure and local protocols. Real-world comparisons continue to show uncertainty about the optimal approach in urgent surgical settings, particularly because the population is heterogeneous and both bleeding and thrombosis are serious risks. A 2026 retrospective neurosurgical comparison of 4F-PCC and andexanet alfa found no statistically significant difference in several major clinical outcomes, illustrating how much uncertainty remains without large randomized perioperative trials.
How does VMX-C001 bypass rather than remove the anticoagulant?
Factor Xa occupies a central position in the coagulation cascade, where it helps generate thrombin and ultimately a stable fibrin clot. Factor Xa inhibitors work by blocking that activity.
VMX-C001 is engineered so the anticoagulant does not inhibit it effectively. The modified protein can therefore participate in coagulation even when circulating concentrations of the patient’s normal Factor Xa remain pharmacologically blocked.
This creates a potentially universal approach across Factor Xa inhibitors because the therapy targets the shared functional consequence rather than designing a different antidote for each molecule. VarmX is also pursuing fixed dosing, which could simplify emergency preparation compared with strategies requiring calculations based on drug, dose or timing.
Those proposed advantages still require Phase 3 validation. Restoring laboratory coagulation parameters does not automatically guarantee good operative hemostasis, and excessive restoration can create thrombotic risk in precisely the patients who were receiving anticoagulation because they were already vulnerable to thrombosis.
Why could compatibility with heparin become an important differentiator?
Some urgent cardiovascular and other procedures require physicians to reverse a patient’s pre-existing oral anticoagulant and then intentionally administer heparin during the operation. A reversal strategy that interferes with subsequent heparin anticoagulation can therefore create an operational problem.
VarmX specifically designed VMX-C001 with this setting in mind and is enrolling patients requiring urgent procedures with or without planned heparin administration. The company says preservation of common anticoagulants such as heparin is one of the potential characteristics being tested in the Phase 3 programme rather than an established clinical advantage.
That distinction could matter particularly in cardiac surgery and procedures involving extracorporeal circulation, where surgeons may need strong anticoagulation during part of the intervention despite wanting the patient’s pre-existing DOAC effect neutralized beforehand.
What will EquilibriX-S measure?
The primary efficacy endpoint is the proportion of participants achieving good or excellent intraoperative hemostasis, with assessment conducted by experts blinded to treatment allocation. Patients will receive either a fixed dose of VMX-C001 or usual pharmacological care before the required procedure, undergo serial clinical and laboratory assessments during hospitalization and return for follow-up at around 28 days.
VarmX says eligible patients will generally have received a Factor Xa inhibitor within the previous 15 hours, placing the study directly into the window where residual anticoagulant activity can be most clinically relevant.
The design is stronger than a biomarker-only programme because the central question is whether surgical bleeding is controlled effectively rather than simply whether anti-Xa laboratory values change. Safety endpoints will also need to establish thrombotic outcomes, since aggressive reversal can trade one acute danger for another.
Why is this a different problem from treating spontaneous major bleeding?
An actively bleeding patient and a patient awaiting emergency surgery both need reversal, but the clinical requirements differ. In spontaneous bleeding, physicians are attempting to stop an event already underway. Before surgery, the goal is to create a sufficiently controlled coagulation state that an intervention can begin safely, sometimes followed by deliberate administration of another anticoagulant during the procedure.
VarmX is also developing VMX-C001 for severe spontaneous bleeding, but EquilibriX-S focuses on urgent surgery and invasive procedures. That allows the company to build evidence around one highly defined decision point rather than combining fundamentally different clinical situations into the same pivotal endpoint.
How large could the need become as DOAC use expands?
VarmX estimates that by 2030 approximately 30 million people across the United States, Europe and Japan could receive Factor Xa inhibitors chronically. The company further estimates that more than 30,000 patients each week experience life-threatening bleeding or require emergency surgery, although those market figures are based on commissioned research and literature rather than a regulatory source.
The commercial opportunity is therefore linked to the success of the anticoagulant class itself. The more physicians use Factor Xa inhibitors for atrial fibrillation and thromboembolism prevention, the larger the population that will occasionally require a rapid way to switch coagulation back on.
FDA granted VMX-C001 Fast Track designation in 2025 for restoration of coagulation in patients on Factor Xa DOACs requiring urgent surgery, signaling recognition of the unmet need without prejudging whether the drug will eventually be approved.
What would make VMX-C001 clinically meaningful rather than simply another reversal option?
Speed, reliability and thrombotic safety will determine its value. Emergency teams need a treatment that can be prepared rapidly, work across commonly used Factor Xa inhibitors and create predictable operative hemostasis without generating excessive thrombosis.
A universal fixed dose could reduce decision complexity at precisely the moment when physicians have little time to investigate what drug was taken, what dose was used and how much active compound remains. Compatibility with later heparinization could add another important procedural advantage if confirmed prospectively.
EquilibriX-S is large enough to test those claims against actual practice rather than historical controls. VarmX has engineered a protein capable of bypassing the molecular problem created by Factor Xa inhibitors. The 800-patient trial now has to prove that elegant coagulation biology produces safer, controllable surgery when the operating room cannot wait for the anticoagulant to disappear naturally.